Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Future Oncol. 2010 Jan;6(1):25-35. doi: 10.2217/fon.09.133.

    Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer.

    Source

    Department of General, Visceral and Cancer Surgery, University of Cologne, Kerpener Str. 62, 50937 Köln, Germany. Elfriede.Bollschweiler@uk-koeln.de

    Abstract

    A review of the literature demonstrated that clinical evaluation cannot be used to determine 'complete response'. The different classification systems of the histopathologic response grading after neoadjuvant radiochemotherapy of esophageal carcinoma are summarized in this report. A systematic review of studies analyzing preoperative chemoradiation of squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus demonstrated no significant difference in pathologic complete response (pCR) rates between the AC and SCC studies. Analyzing only the applied dose of radiation demonstrated that patients with AC required a higher dose than patients with SCC to achieve complete response. Incorporating chemotherapy administration does not markedly change the difference in required radiation dose. However, when the tumor does respond, the rate of pCR with increasing dosage of chemoradiotherapy increases more rapidly in AC patients than in SCC patients.

    PMID:
    20021207
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Atypon

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk